AIM ImmunoTech received Orphan Drug Designation for Ampligen (rintatolimod) for treatment of Ebola virus disease
On Nov. 2, 2022, AIM ImmunoTech announced that the U.S. Food and Drug Administration had granted Orphan Drug Designation to Ampligenﾮ (rintatolimod) for the treatment of Ebola virus disease.
Tags:
Source: AIM ImmunoTech
Credit:
